Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study

BACKGROUND: PQ912 is an inhibitor of the glutaminyl cyclase enzyme that plays a central role in the formation of synaptotoxic pyroglutamate-A-beta oligomers. We report on the first clinical study with PQ912 in subjects with biomarker-proven Alzheimer’s disease (AD). The aim was to determine the maxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Scheltens, Philip, Hallikainen, Merja, Grimmer, Timo, Duning, Thomas, Gouw, Alida A, Teunissen, Charlotte E, Wink, Alle Meije, Maruff, Paul, Harrison, John, van Baal, Caroline M, Bruins, Suzanne, Lues, Inge, Prins, Niels D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182869/
https://www.ncbi.nlm.nih.gov/pubmed/30309389
http://dx.doi.org/10.1186/s13195-018-0431-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182869/
https://www.ncbi.nlm.nih.gov/pubmed/30309389
http://dx.doi.org/10.1186/s13195-018-0431-6

Ejemplares similares